Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fifteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $137.3125.

Several equities analysts have weighed in on the company. UBS Group set a $137.00 price target on Mirum Pharmaceuticals in a research report on Thursday. Raymond James Financial restated a "strong-buy" rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Wolfe Research initiated coverage on Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They set an "outperform" rating and a $145.00 price objective for the company. Royal Bank Of Canada cut their target price on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an "overweight" rating in a report on Thursday, July 2nd.

Mirum Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ MIRM opened at $98.05 on Tuesday. The firm's 50-day moving average is $110.44 and its two-hundred day moving average is $101.78. The company has a market capitalization of $6.37 billion, a PE ratio of -6.74 and a beta of 0.52. Mirum Pharmaceuticals has a 12-month low of $63.23 and a 12-month high of $130.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The business had revenue of $176.24 million for the quarter, compared to analysts' expectations of $166.33 million. During the same period last year, the business earned ($0.12) earnings per share. The company's revenue for the quarter was up 37.9% on a year-over-year basis. Equities analysts anticipate that Mirum Pharmaceuticals will post -1.31 EPS for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In related news, CFO Eric Bjerkholt sold 6,001 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the transaction, the chief financial officer owned 36,355 shares of the company's stock, valued at approximately $3,631,864.50. This represents a 14.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the sale, the senior vice president owned 1,274 shares in the company, valued at approximately $127,400. This trade represents a 96.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 103,156 shares of company stock worth $10,888,362 over the last ninety days. 8.32% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Cullen Frost Bankers Inc. acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth $30,000. Eurizon Capital SGR S.p.A. acquired a new position in Mirum Pharmaceuticals in the fourth quarter valued at $32,000. CIBC Private Wealth Group LLC acquired a new position in Mirum Pharmaceuticals in the fourth quarter valued at $32,000. Quantbot Technologies LP purchased a new position in Mirum Pharmaceuticals during the third quarter worth about $33,000. Finally, Comerica Bank boosted its stake in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company's stock worth $40,000 after buying an additional 278 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source